Research as an event: A novel approach to promote patient-focused drug development

Jui Hua Tsai, Ellen Janssen, John F.P. Bridges

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Patient groups are increasingly engaging in research to understand patients’ preferences and incorporate their perspectives into drug development and regulation. Several models of patient engagement have emerged, but there is little guidance on how to partner with patient groups to engage the disease community. Our group has been using an approach to engage patient groups that we call research as an event. Research as an event is a method for researchers to use a community-centered event to engage patients in their own environment at modest incremental cost. It is a pragmatic solution to address the challenges of engaging patients in research to minimize patients’ frustration, decrease the time burden, and limit the overall cost. The community, the event, and the research are the three components that constitute the research as an event framework. The community represents a disease-specific community. The event is a meeting of common interest for patients and other stakeholders, such as a patient advocacy conference. The research describes activities in engaging the community for the purpose of research. Research as an event follows a six-step approach. A case study is used to demonstrate the six steps followed by recommendations for future implementation.

Original languageEnglish (US)
Pages (from-to)673-679
Number of pages7
JournalPatient Preference and Adherence
StatePublished - May 3 2018
Externally publishedYes


  • Decision making
  • Drug approval
  • Patient engagement
  • Patient organization
  • Patients’ perspectives
  • Patients’ preference

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy


Dive into the research topics of 'Research as an event: A novel approach to promote patient-focused drug development'. Together they form a unique fingerprint.

Cite this